Objective: The purpose of this study was to investigate the effects of sacubitril/valsartan on cardiac function and nutritional status in elderly patients with heart failure in ischemic cardiomyopathy.Methods: A total of 118 elderly patients with heart failure due to ischemic cardiomyopathy in Tangshan Gongren Hospital were randomly divided into enalapril group(ACEI group,n=61cases)and sacubitril/valsartan group(ARNI group,n=57cases).We analyze the changes in left ventricular ejection fraction(LVEF),left ventricular end-diastolic diameter(LVEDD),left ventricular end-systolic diameter(LVESD),left ventricular mass index(LVMI),N-terminal pro-brain natriuretic peptide(NT-pro BNP),Kansas City cardiomyopathy questionnaire(KCCQ)score,albumin(ALB),prealbumin(PA)and the geriatric nutritional risk index(GNRI)score after 6 months of treatment in the two groups.Results:1.There were no significant differences in LVEF,LVEDD,LVESD,LVMI,NT-pro BNP,KCCQ score,ALB,PA and GNRI score between the two groups before treatment(P>0.05).2.After 6 months of treatment,in both of the two groups,LVEF,KCCQ score were increased,LVEDD,LVESD,LVMI and NT-pro BNP were decreased,and all the differences were statistically significant(P<0.05);furthermore,the LVEF,KCCQ score,LVEDD,LVESD,LVMI and NT-pro BNP of the ARNI group were significantly improved compared with the ACEI group(P<0.05).3.After 6 months of treatment,in the ARNI group,the ALB,PA and GNRI score were all increased with statistically significant differences(P<0.05);there were no significant differences in ALB,PA and GNRI among the ACEI group after treatment(P>0.05).4.After treatment,the probability of adverse reaction events in the two groups was not statistically significant(P>0.05).Conclusion: Sacubitril/valsartan can not only effectively improve the cardiac function and nutritional status of elderly patients with heart failure in ischemic cardiomyopathy,but also improve the quality of life and the prognosis. |